COST EFFECTIVENESS ANALYSIS OF IMPLEMENTING A SCREENING PROGRAM FOR EARLY-STAGE ALZHEIMER’S DISEASE DETECTION
Yeongin Jung, Kaili Wu, Mashael Alnufeay, Xiaotong Jin, Jeromie Ballreich, Emmanuel Drabo · 2024
Read COST EFFECTIVENESS ANALYSIS OF IMPLEMENTING A SCREENING PROGRAM FOR EARLY-STAGE ALZHEIMER’S DISEASE DETECTION by Yeongin Jung, Kaili Wu, Mashael Alnufeay, Xiaotong Jin, Jeromie Ballreich, Emmanuel Drabo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692758.txt.
Description
Yeongin Jung and co-authors weigh in 2024 the cost value of screening for early Alzheimer disease with a blood marker. New drugs and blood tests make early finds more feasible than before. Two plans face off for adults aged sixty five and up with early brain changes.
One plan uses the blood test alone, while the other adds a brain scan to confirm positives. A hybrid model tracks costs, health gains, and disease stages over thirty five years for a thousand-person cohort. The blood-only plan wins on both axes in the runs. It adds near nine hundred quality life years in the model at lower added cost.
Catalog record
| CREATOR | Yeongin Jung, Kaili Wu, Mashael Alnufeay, Xiaotong Jin, Jeromie Ballreich, Emmanuel Drabo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |